Evidence map›Paper›PMID 33217046›Full record

ReviewJournal of clinical pharmacy and therapeutics2021

The Zika virus: Lurking behind the COVID-19 pandemic?

Joseph Pergolizzi, Jo Ann LeQuang, Sumiyo Umeda-Raffa, Charles Fleischer, Joseph Pergolizzi, Claudio Pergolizzi, Robert B Raffa

Abstract readReview
In one paragraph

Review in Journal of clinical pharmacy and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The burden of global outbreaks: Photos of the daily lives of children with congenital Zika syndrome during the COVID-19 pandemic.Health expectations : an international journal of public participation in health care and health policy · 2023
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Meeting the Need for a Discussion of Unmet Medical Need.Healthcare (Basel, Switzerland) · 2022
    Article
  12. Review
  13. Article
  14. The Zika virus: Lurking behind the COVID-19 pandemic?Journal of clinical pharmacy and therapeutics · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Joseph PergolizziNeumentum Inc., Summit, NJ, USA.ORCID https://orcid.org/0000-0001-5658-1471
Jo Ann LeQuangNEMA Research Inc., Naples, FL, USA.
Sumiyo Umeda-RaffaPharmaceutical Sciences (Form. Faculty), Hokkaido University of Science, Sapporo, Japan.
Charles FleischerNEMA Research Inc., Naples, FL, USA.
Joseph PergolizziNEMA Research Inc., Naples, FL, USA.
Claudio PergolizziNEMA Research Inc., Naples, FL, USA.
Robert B RaffaNeumentum Inc., Summit, NJ, USA.ORCID https://orcid.org/0000-0002-1456-4451

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

WHAT IS KNOWN AND

objectiveThe sudden and extensive outbreak of coronavirus (SARS-CoV-2) has overshadowed another developing viral threat: the Zika flavivirus. Of particular concern is that pregnant women can pass Zika virus to the foetus, and there is a strong implication of an association between Zika virus infection and foetal microcephaly. Currently, there is no vaccine, and there is no cure.

methodsPublished literature and Internet sources were searched for information related to Zika virus, its transmission, its clinical presentation and sequalae, prevention and implications (practice and regulatory) for healthcare providers. The identified English sources were reviewed, assessed and synthesized. Emphasis was placed on providing an overview of the problem, and identification of unmet needs and future directions. RESULTS AND DISCUSSION: Zika virus poses a major challenge for healthcare providers, particularly in areas unaccustomed to it, since it is transmitted to humans by the vector Aedes aegypti mosquito. The outbreak impacts every healthcare provider, because every provider is required to report cases of Zika infection to their state or local health agencies--whether the infection is confirmed or merely suspected. Since the virus has become a worldwide crisis, healthcare providers will need to work across national boundaries and medical disciplines in order to educate patients about Zika symptoms and the mosquito vector. Until further information is known, infected patients (male and female) are being advised to avoid conceiving a child. WHAT IS NEW AND

conclusionUntil a vaccine is developed or effective treatment for Zika virus is discovered, healthcare providers must be AVP (aware, vigilant and proactive) in order to lessen the spread and impact of the implicated devastating birth defects (microcephaly) and other neurological disorders (eg Guillain-Barré Syndrome) of this infection. Unfortunately, many knowledge gaps exist. There is an urgent need for a reliable, inexpensive diagnostic test, an effective treatment and an approved and readily available vaccine.

Indexed as

Communicable Disease ControlZika VirusZika Virus InfectionChain of InfectionCOVID-19Disease Transmission, InfectiousHealth Services Needs and DemandHumansSARS-CoV-2Aedes aegyptiGuillain-Barré syndromemicrocephalyvaccineZika virus

Identifiers

PMID33217046
PMCPMC7753281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.